Jahresbericht der Klinik - Klinik für Kardiologie - UniversitätsSpital ...

Thomas F. Lüscher, MD, FRCP
Primary Investigator
Christian M. Matter, MD
Research Coordinator
Special University Program: Swiss ACS Inflammation Cohort
Continued Support of the SNF for
Acute Coronary Syndromes
Acute coronary syndromes (ACS) are the most frequent cause of heart
failure and death. Inflammatory pathways may trigger plaque rupture.
The complication rate of ACS remains high since (1) triggers of plaque
rupture are poorly understood, (2) diagnosis is made late, (3) the concept
of inflammation is not incorporated into clinical decision making,
(4) individual patient risk remains poorly defined and (5) secondary
prevention is poorly developed and not well implemented.
To improve outcome, novel diagnostic and prognostic markers must
be evaluated, the value of high-resolution imaging determined, antiinflammatory
treatment strategies developed and caregiver and patient
education optimized. These aims of 2009 – 2012 will be pursued
and completed within the next 3 years 2012 – 2015 [Fig. 1] with generous
funding from the SNF and additional support by industry (Eli
Lilly, AstraZeneca, Biosensors, Roche, St. Jude Medical).
Aim 1 Discovery of novel molecular and cellular mechanisms
of plaque rupture
C. M. Matter, T. F. Lüscher, Zurich
Aim 2 Intracoronary imaging of atherosclerosis
S. Windecker, Bern
Aim 3 Evaluation of candidate biomarkers for diagnosis,
prognosis and anti-inflammatory strategies
W. Maier, T. F. Lüscher, C. M. Matter, Zurich, F. Mach, Geneva
Aim 4 Characterization of the role of progenitor cellmediated
repair in ACS
U. Landmesser, T. F. Lüscher, Zurich
Aim 5 Optimization of care and prevention after ACS by
improving caregiver and patient education
P-F. Keller, F. Mach, Geneva, N. Rodondi, P. Vogt, Lausanne
Aim 6 Implementation of a nationwide systematic smoking
cessation program
N. Rodondi, J. Cornuz, P. Vogt, Lausanne
So far, we recruited 1700 patients into the biomarker cohort, over
1000 and 100 patients respectively into the interventional COM-
FORTABLE AMI and imaging IBIS-4 trial and 2100 patients into the
secondary prevention ELIPS program and 500 in the MYRIAD diagnostic
pilot evaluating MRP 8 / 14. Further, the expression profile of
inflammatory and progenitor cells in peripheral blood and coronary
thrombi was characterized. Part of the results have been published
or submitted.
Fig. 1 Scheme showing research aims of the prolongation of the
ACS-inflammation cohort study 2012 – 2015 performed in Bern,
Geneva, Lausanne, and Zurich.
This project was and will be realized thanks to the hard work of previous
and future SPUM fellows (Christian Templin, Lukas Altwegg,
Roland Klingenberg, Matthias Hasun, Milosz Jaguscewski, Barbara
Stähli, Philipp Jakob) and SPUM study nurses (Anika Lewandowski,
Sandra Corrieri).